BrainSpec
BrainSpec offers FDA-cleared, AI-assisted magnetic resonance spectroscopy software that measures brain chemistry non-invasively.
Competitive Advantages
BrainSpec holds full FDA clearance for AI-assisted non-invasive brain chemistry measurement, a regulatory moat few spectroscopy competitors can claim. Its cloud-based workflow with automated reporting and multi-vendor scanner support lowers adoption barriers for hospitals.
Research validation strengthens its position, including a University of Minnesota collaboration on automated voxel placement and a 65-subject Washington University study showing strong mild traumatic brain injury detection. Backing from DCVC and other institutional investors funds continued clinical expansion.
Source: medicaldevice-network.com
Market Outlook
BrainSpec is headquartered at 665 Washington Street in Boston, placing it inside a leading neuroimaging and hospital research cluster. Demand for non-invasive quantitative brain diagnostics is growing across neurology, neurosurgery, and psychiatry practices.
The company has raised about 1.88 million dollars across five rounds, with DCVC leading its first institutional investment. Continued FDA-cleared deployments and academic partnerships point to widening clinical use of automated spectroscopy.
Source: dcvc.com
Product Overview
BrainSpec Core is a web-based magnetic resonance spectroscopy platform that measures brain chemistry non-invasively. It combines cloud processing, a browser-based viewer, and PACS pull and push with support for DICOM, RDA, TWIX, SDAT, and G-file formats.
The platform generates automated reports and works across GE, Siemens, and Philips scanners. Clinical applications span brain tumor, traumatic brain injury, Parkinson's disease, multiple sclerosis, Alzheimer's disease, epilepsy, schizophrenia, and hypoxic-ischemic encephalopathy.
Source: brainspecmed.com